Purdue Pharma teams up with Alivio Therapeutics to advance ALV-107
Category: #health  By Mateen Dalal  Date: 2019-01-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Purdue Pharma teams up with Alivio Therapeutics to advance ALV-107

Purdue Pharma L.P., the Connecticut-based pharmaceutical company, has reportedly announced that it has signed a partnership agreement with Alivio Therapeutics to advance one of its product candidates via clinical development.

As per trusted sources, Purdue Pharma would have an option to invest in the next equity financing of Alivio Therapeutics. Reportedly, Alivio is eligible to receive royalties on product sales and more than USD 260 million in R&D milestones. Moreover, the firm is also slated to be paid up to USD 14.75 million in upfront and near-term license exercise payments.

President and Chief Executive Officer of Purdue Pharma, Craig Landau M.D., was reportedly quoted saying that the latest partnership is a significant milestone in the company’s continued pursuit of non-opioid treatments for pain and underscores a major step to further diversify product portfolio. Purdue Pharma is impressed with the innovative platform technology of Alivio as it focuses on meeting the patient needs, especially in regions where very few treatment options are available, Landau further added.

For the record, ALV-107 is a non-opioid treatment presently being developed for interstitial cystitis/bladder pain syndrome. Sources familiar with the development claim that the ALV-107 program recently secured a USD 3.3 million U.S. Department of Defense (DoD) Technology/Therapeutic Development Award. The funds would be utilized to back the preclinical R&D activities, including GMP manufacturing and ensure the filing of an investigational new drug (IND) application.

Chief Innovation Officer of PureTech and a Co-founder of Alivio Therapeutics, Eric Elenko, PhD, reportedly commented that the company is delighted to forge the new collaboration aimed at advancing ALV-07 for the potential treatment of interstitial cystitis/bladder pain syndrome. Alivio is swiftly progressing its potential application across inflammatory bowel and pouchitis disease as part of its internal R&D lab.

Moreover, the platform technology of the firm has been created to resolve numerous inflammatory conditions and the non-opioid approach may provide a unique novel treatment option for an ailment where there is a humongous unmet need, Elenko further added.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...